Skip to main content

Table 1 Outcome of triage by HPV test (n = 564)

From: 5-type HPV mRNA versus 14-type HPV DNA test: test performance, over-diagnosis and overtreatment in triage of women with minor cervical lesions

  DNA 5-type-mRNA
N = 564 % (95 % CI) N = 564 % (95 % CI)
Back to screening 399 70.7 (66.9–74.5) 459 81.4 (78.2–84.6)*
Met for biopsy 105 18.6 (15.4–21.8) 77 13.7 (10.9–16.5)
Scheduled, not met for biopsy 36 6.4 (4.4–8.4) 15 2.7 (1.4–4.0)*
Incomplete follow-up 24 4.3 (2.6–6.0) 13 2.3 (1.1–3.5)
  1. *p < 0.05
  2. Triage repeat cytology and HPV test 3–18 months after index ASC-US/LSIL cytology
  3. DNA HPV DNA test (Cobas 4800)
  4. 5-type-mRNA HPV mRNA test (PreTect HPV-Proofer)